(Q38182651)

30 August 2017

title

Dyskinesias in Parkinson's disease: views from positron emission tomography studies (English)

1 reference

positron emission tomography

30 August 2017

1 reference

1 reference

1 reference

F Niccolini

1

1 reference

30 August 2017

C Loane

series ordinal

2

1 reference

30 August 2017

M Politis

series ordinal

3

1 reference

30 August 2017

publication date

28 January 2014

1 reference

European Journal of Neurology

30 August 2017

published in

1 reference

30 August 2017

volume

21

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

694-9, e39-43

1 reference

30 August 2017

1 reference

Parkinson's disease symptoms: the patient's perspective

21 January 2018

1 reference

21 January 2018

Basal ganglia disease

1 reference

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway

21 January 2018

1 reference

21 January 2018

1 reference

Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data

21 January 2018

1 reference

Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study

21 January 2018

1 reference

Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability

21 January 2018

1 reference

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease

21 January 2018

1 reference

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

21 January 2018

1 reference

The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain

21 January 2018

1 reference

Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia

21 January 2018

1 reference

CB1 cannabinoid receptor signalling in Parkinson's disease

21 January 2018

1 reference

High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.

21 January 2018

1 reference

Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

21 January 2018

1 reference

Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.

21 January 2018

1 reference

Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism

21 January 2018

1 reference

Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's chorea

21 January 2018

1 reference

A subcortico-cortical cholinergic system is affected in Parkinson's disease

21 January 2018

1 reference

Enhanced striatal cholinergic neuronal activity mediatesl-DOPA–induced dyskinesia in parkinsonian mice

21 January 2018

1 reference

Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson's disease

21 January 2018

1 reference

Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease

21 January 2018

1 reference

Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease

21 January 2018

1 reference

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

21 January 2018

1 reference

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

21 January 2018

1 reference

Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up

21 January 2018

1 reference

Dyskinesia after fetal cell transplantation for parkinsonism: a PET study

21 January 2018

1 reference

Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis

21 January 2018

1 reference

Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

21 January 2018

1 reference

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?

21 January 2018

1 reference

Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio.

21 January 2018

1 reference

Brain imaging after neural transplantation

21 January 2018

1 reference

In vivo imaging of the integration and function of nigral grafts in clinical trials

21 January 2018

1 reference

Positron emission tomography imaging in neurological disorders

21 January 2018

1 reference

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

21 January 2018

1 reference

Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies

21 January 2018

1 reference

Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition

21 January 2018

1 reference

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

Endogenous dopamine release after pharmacological challenges in Parkinson's disease.

21 January 2018

1 reference

Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study

21 January 2018

1 reference

PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

21 January 2018

1 reference

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

21 January 2018

1 reference

Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications.

21 January 2018

1 reference

In vivo studies on striatal dopamine D 1 and D 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias

21 January 2018

1 reference

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease

21 January 2018

1 reference

Aminergic systems in Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease

21 January 2018

1 reference

Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

21 January 2018

1 reference

Serotonergic mediated body mass index changes in Parkinson's disease.

21 January 2018

1 reference

Brain serotonin transporter binding in non-depressed patients with Parkinson's disease

21 January 2018

1 reference

Spared caudal brainstem SERT binding in early Parkinson's disease

21 January 2018

1 reference

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

L-Dopa-Induced Release of Cerebral Monoamines

21 January 2018

1 reference

Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats

21 January 2018

1 reference

Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA.

21 January 2018

1 reference

Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation

21 January 2018

1 reference

5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy

21 January 2018

1 reference

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

21 January 2018

1 reference

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

21 January 2018

1 reference

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy

21 January 2018

1 reference

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

21 January 2018

1 reference

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.

21 January 2018

1 reference

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats

21 January 2018

1 reference

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

21 January 2018

1 reference

Buspirone: What is it all about?

21 January 2018

1 reference

Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.

21 January 2018

1 reference

Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment

21 January 2018

1 reference

Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.

21 January 2018

1 reference

Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

21 January 2018

1 reference

Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities

21 January 2018

1 reference

Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA

21 January 2018

1 reference

Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias

21 January 2018

1 reference

Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients

21 January 2018

1 reference

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

21 January 2018

1 reference

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

21 January 2018

1 reference

Subtraction autoradiography of opiate receptor subtypes in human brain.

21 January 2018

1 reference

Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia

21 January 2018

1 reference

Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

21 January 2018

1 reference

Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats

21 January 2018

1 reference

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

21 January 2018

1 reference

Cannabinoid receptors and their endogenous agonists

21 January 2018

1 reference

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

21 January 2018

1 reference

Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

21 January 2018

1 reference

Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain

21 January 2018

1 reference

Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias

21 January 2018

1 reference

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study

21 January 2018

1 reference

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

21 January 2018

1 reference

Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease

21 January 2018

1 reference

The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats

21 January 2018

1 reference

Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms

21 January 2018

1 reference

Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study

21 January 2018

1 reference

The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain

21 January 2018

1 reference

Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand

21 January 2018

1 reference

In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography

21 January 2018

1 reference

Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways

21 January 2018

1 reference

Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.

21 January 2018

1 reference

Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys

21 January 2018

1 reference

Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.

21 January 2018

1 reference

The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease

21 January 2018

1 reference

Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.

21 January 2018

1 reference

Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

21 January 2018

1 reference

Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2.

21 January 2018

1 reference

Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2.

21 January 2018

1 reference

Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2.

21 January 2018

1 reference

Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress

21 January 2018

1 reference

Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease

21 January 2018

1 reference

Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants

21 January 2018

1 reference

Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease

21 January 2018

1 reference

Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease

21 January 2018

1 reference

Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's disease. Clinica Puerta de Hierro Neural Transplantation Group

21 January 2018

1 reference

Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

21 January 2018

1 reference

Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon.

21 January 2018

1 reference

Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients

21 January 2018

1 reference

Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts

21 January 2018

1 reference

Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia

21 January 2018

1 reference

Factors affecting the clinical outcome after neural transplantation in Parkinson's disease

21 January 2018

1 reference

Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants

21 January 2018

1 reference

Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.

21 January 2018

1 reference

Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ENE.12362

1 reference

30 August 2017

1 reference